TSL.L Regulatory News (TSL)

25 Jul 2005 10:18

Tissue Science Laboratories PLC25 July 2005 25 July 2005 Tissue Science Laboratories plc ('TSL' or 'the Company') TSL Acquires New Manufacturing Facility Tissue Science Laboratories plc (LSE: TSL), the medical devices companyspecialising in human tissue replacement and repair products derived fromporcine dermis, is pleased to announce the acquisition of a new industrial unitnear Leeds forc.£1.7 million. The new freehold is approximately 30,000 square feet and will provide newoffices, laboratories, warehousing and manufacturing space. It is a shortdistance from the current manufacturing facility in Swillington and it willprovide space for the Company's product development programmes. The facilitywill be phased in over a three year period as part of the planned development ofthe business. The acquisition has been financed with a 20 year commercial mortgage provided byBarclay's Bank. Martin Hunt, Chief Executive of TSL, said:"With the planned acceleration of our product development, the securing of thisnew space has been essential to our continued growth. We see this as anothermilestone in the Company's development and we are excited about the potentialopportunities this will enable us to exploit." -Ends- For further information, please contact: TSL plc Tel: 01252 369603Martin Hunt, Chief Executive Hogarth Partnership Limited Tel: 020 7357 9477Melanie Toyne-Sewell / Kate Catchpole Notes to Editors Background on TSL Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medicaltechnology company specialising in tissue repair and replacement with aproprietary sheet product, derived from porcine dermis, called Permacol(R). TSLhas successfully launched different formulations of the product and built adevelopment pipeline that addresses the large and fast growing surgical implantmarket. The Company floated in November 2001 and is listed on the AIM (LSE:TSL). TSL has a family of products based on the same core technology. Each producthas been adapted, with unique properties, to make it suitable for use indifferent applications, including urology/gynaecology, complex and recurrenthernia repair, shoulder rotator cuff repair and head and face repair andreconstruction. The Company has signed distribution agreements with CR Bard Inc(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) andPorex Surgical Inc (head & face-US and Canada). Further variations of the sheetand injectable forms of Permacol(R) are being developed. Background on Permacol(R) Permacol(R) was developed at Dundee University over a 20 year time period andhas been patented worldwide. The key to the Permacol(R) concept lies in itscollagen Technology which uses non-reconstituted porcine dermal collagen, verysimilar in structure to human tissue. Non-collagenous material, except elastin,is removed by the TSL manufacturing process. The remaining collagen, whichretains its original 3-D structural architecture, is stabilised by a patentedcross-linking process. The result is a non-reconstituted, non-allergenic,collagen implant which is resistant to biodegradation attack, is recognised andaccepted by the body, and is able to provide a long-term support for thein-growth of new tissue and its associated blood supply. This information is provided by RNS The company news service from the London Stock Exchange